TREM-1，抗TNF治疗的克罗恩病患者内镜愈合的理想预测生物标志物？ - Suppr

TREM-1, the ideal predictive biomarker for endoscopic healing in anti-TNF-treated Crohn's disease patients?

作者信息

Verstockt Bram, Verstockt Sare, Blevi Helene, Cleynen Isabelle, de Bruyn Magali, Van Assche Gert, Vermeire Séverine, Ferrante Marc

机构信息

Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.

Department of Chronic Diseases, Metabolism and Ageing, Translational Research Centre for Gastrointestinal Disorders (TARGID-IBD), KU Leuven, Leuven, Belgium.

出版信息

Gut. 2019 Aug;68(8):1531-1533. doi: 10.1136/gutjnl-2018-316845. Epub 2018 Jul 14.

DOI:10.1136/gutjnl-2018-316845

PMID:30007919

Abstract

摘要

相似文献

TREM-1, the ideal predictive biomarker for endoscopic healing in anti-TNF-treated Crohn's disease patients?TREM-1，抗TNF治疗的克罗恩病患者内镜愈合的理想预测生物标志物？

Gut. 2019 Aug;68(8):1531-1533. doi: 10.1136/gutjnl-2018-316845. Epub 2018 Jul 14.

Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.用于维持克罗恩病缓解的肿瘤坏死因子-α抗体。

Cochrane Database Syst Rev. 2008 Jan 23(1):CD006893. doi: 10.1002/14651858.CD006893.

Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.英夫利昔单抗和其他抗肿瘤坏死因子 α 治疗药物治疗炎症性肠病。

BioDrugs. 2010 Dec 14;24 Suppl 1:3-14. doi: 10.2165/11586290-000000000-00000.

[Anti-TNF therapy in treatment of luminal Crohn's disease].[抗TNF治疗在腔内型克罗恩病治疗中的应用]

Acta Med Croatica. 2013 Apr;67(2):179-89.

Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study.与英夫利昔单抗相比，接受阿达木单抗治疗的克罗恩病门诊患者出现继发性反应丧失和需要增加剂量的时间更早：一项真实队列研究。

J Crohns Colitis. 2014 Nov;8(11):1454-63. doi: 10.1016/j.crohns.2014.05.007. Epub 2014 Jun 16.

Stricturing and Fistulizing Crohn's Disease Is Associated with Anti-tumor Necrosis Factor-Induced Psoriasis in Patients with Inflammatory Bowel Disease.炎症性肠病患者的狭窄和瘘管形成克罗恩病与抗肿瘤坏死因子诱导的银屑病有关。

Dig Dis Sci. 2018 Sep;63(9):2430-2438. doi: 10.1007/s10620-018-5096-2. Epub 2018 May 8.

Magnetic resonance enterography changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn's disease: correlation with SES-CD and clinical-biological markers.克罗恩病患者接受肿瘤坏死因子α抗体（抗TNF）治疗后磁共振小肠造影的变化：与SES-CD及临床生物学标志物的相关性

BMC Med Imaging. 2016 May 5;16(1):37. doi: 10.1186/s12880-016-0139-7.

Tissue Drug Concentrations of Anti-tumor Necrosis Factor Agents Are Associated with the Long-term Outcome of Patients with Crohn's Disease.肿瘤坏死因子拮抗剂在组织中的浓度与克罗恩病患者的长期预后相关。

Inflamm Bowel Dis. 2017 Dec;23(12):2172-2179. doi: 10.1097/MIB.0000000000001260.

Long-term MRI-guided combined anti-TNF-α and thiopurine therapy for Crohn's perianal fistulas.MRI 引导下长期联合使用抗 TNF-α 药物和巯嘌呤治疗克罗恩病肛周瘘管。

Inflamm Bowel Dis. 2012 Oct;18(10):1825-34. doi: 10.1002/ibd.21940. Epub 2012 Jan 4.

Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial.英夫利昔单抗抗肿瘤坏死因子抗体用于克罗恩病的内镜及组织学愈合：一项欧洲多中心试验

Gastroenterology. 1999 May;116(5):1029-34. doi: 10.1016/s0016-5085(99)70005-3.

引用本文的文献

Multi-Omics Biomarkers for Predicting Efficacy of Biologic and Small-Molecule Therapies in Adults With Inflammatory Bowel Disease: A Systematic Review.用于预测生物制剂和小分子疗法对成人炎症性肠病疗效的多组学生物标志物：一项系统评价

United European Gastroenterol J. 2025 May;13(4):517-530. doi: 10.1002/ueg2.12720. Epub 2024 Dec 10.

Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients.英夫利昔单抗和阿达木单抗治疗炎症性肠病患者的疗效和安全性。

Inflammopharmacology. 2024 Oct;32(5):3259-3269. doi: 10.1007/s10787-024-01508-w. Epub 2024 Jul 10.

Biomarkers That Predict Crohn's Disease Outcomes.预测克罗恩病预后的生物标志物。

J Can Assoc Gastroenterol. 2023 Sep 2;7(1):59-67. doi: 10.1093/jcag/gwad024. eCollection 2024 Feb.

Whole blood coagulation in an ex vivo thrombus is sufficient to induce clot neutrophils to adopt a myeloid-derived suppressor cell signature and shed soluble Lox-1.在体外血栓中，全血凝固足以诱导血栓中性粒细胞采用髓系来源的抑制细胞特征，并释放可溶性 Lox-1。

J Thromb Haemost. 2024 Apr;22(4):1031-1045. doi: 10.1016/j.jtha.2023.12.014. Epub 2023 Dec 20.

Baseline TREM-1 Whole Blood Gene Expression Does Not Predict Response to Adalimumab Treatment in Patients with Ulcerative Colitis or Crohn's Disease in the SERENE Studies.在SERENE研究中，溃疡性结肠炎或克罗恩病患者的基线全血TREM-1基因表达不能预测对阿达木单抗治疗的反应。

J Crohns Colitis. 2024 Apr 23;18(4):493-505. doi: 10.1093/ecco-jcc/jjad170.

Baseline Expression of Immune Gene Modules in Blood is Associated With Primary Response to Anti-TNF Therapy in Crohn's Disease Patients.免疫基因模块在血液中的基础表达与克罗恩病患者对 TNF 拮抗剂治疗的初始应答相关。

J Crohns Colitis. 2024 Mar 1;18(3):431-445. doi: 10.1093/ecco-jcc/jjad166.

Harnessing the Power of Precision Medicine and Novel Biomarkers to Treat Crohn's Disease.利用精准医学和新型生物标志物的力量治疗克罗恩病。

J Clin Med. 2023 Apr 4;12(7):2696. doi: 10.3390/jcm12072696.

Precision medicine in inflammatory bowel disease: Individualizing the use of biologics and small molecule therapies.炎症性肠病的精准医学：生物制剂和小分子治疗药物的个体化应用。

World J Gastroenterol. 2023 Mar 14;29(10):1539-1550. doi: 10.3748/wjg.v29.i10.1539.

Pursuing neutrophils: systematic scoping review on blood-based biomarkers as predictors of treatment outcomes in inflammatory bowel disease.追踪中性粒细胞：关于基于血液的生物标志物作为炎症性肠病治疗结果预测指标的系统综述

Therap Adv Gastroenterol. 2023 Mar 11;16:17562848231155987. doi: 10.1177/17562848231155987. eCollection 2023.

Development of a Machine Learning Model to Predict Non-Durable Response to Anti-TNF Therapy in Crohn's Disease Using Transcriptome Imputed from Genotypes.利用从基因型推算出的转录组开发机器学习模型以预测克罗恩病患者对抗肿瘤坏死因子治疗的非持久反应

J Pers Med. 2022 Jun 9;12(6):947. doi: 10.3390/jpm12060947.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

TREM-1, the ideal predictive biomarker for endoscopic healing in anti-TNF-treated Crohn's disease patients?

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献